COMP <GO>
BIO vs AVTR // EV/EBITDA & P/E VALUATION
Bio-Rad Laboratories Inc. (NYSE) VS. Avantor Inc. (NYSE) • 15-METRIC TALLY: BIO 10
— AVTR 2
■ METRIC PARITY
LAST: $372.18 (-3.18%) • MKT CAP: $10.28B
valuation
60.4x
LAST: $16.05 (-3.78%) • MKT CAP: $11.30B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. AVTR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | AVTR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 32.70% | +19.20 | BIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | -2.10% | +2.60 | BIO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 60.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 4.38% | -0.74 | AVTR | /fcf-yield <GO> |
| Operating Margin | 1.80% | -3.80% | +5.60 | BIO | /operating-margins <GO> |
| Net Profit Margin | 29.40% | -8.10% | +37.50 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | -3.40% | +4.10 | BIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 1.88 | +1.71 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | BIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 57.4 | +1.60 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.01 | +0.03 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 31.0x | -18.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $11.30B | -$1.02B | AVTR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | AVTR REV | BIO GROSS % | AVTR GROSS % | BIO FCF | AVTR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $6.55B | 51.9% | 32.7% | $374.6M | $495.0M |
| FY 2024 | $2.57B | $6.78B | 53.7% | 33.6% | $289.6M | $692.0M |
| FY 2023 | $2.67B | $6.97B | — | — | $254.7M | $556.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
AVTR // BETA 1.01